Share on StockTwits

In a development that raises a host of ethical issues, Spain announced it had obtained a scarce U.S.-made experimental Ebola drug to treat a Spanish missionary priest infected with the killer virus. The Health Ministry statement came less than a week after the U.S. Centers for Disease Control and Prevention said there were virtually no doses available of the drug that was used to treat two Americans with the disease. The drug’s maker, Mapp Pharmaceutical Inc. of San Diego, says “very little of the drug is currently available” and that is cooperating with government agencies to increase production as quickly as possible.



“Ethical Questions Emerge Over Who Gets Ebola Drug” is categorized as “world”. This video was licensed from Grab Networks. For additional video content, click the “video” tab at the top of this page.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.